TWI773730B - 治療性樹枝狀聚合物 - Google Patents

治療性樹枝狀聚合物 Download PDF

Info

Publication number
TWI773730B
TWI773730B TW107105033A TW107105033A TWI773730B TW I773730 B TWI773730 B TW I773730B TW 107105033 A TW107105033 A TW 107105033A TW 107105033 A TW107105033 A TW 107105033A TW I773730 B TWI773730 B TW I773730B
Authority
TW
Taiwan
Prior art keywords
dendrimer
pharmaceutically acceptable
formula
acceptable salt
iii
Prior art date
Application number
TW107105033A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841659A (zh
Inventor
馬力安尼 配尼斯 阿西福特
艾恩 葛蘭特
艾德華 約翰 漢尼斯
威廉 姆庫爾
麥可 吉安尼斯
布萊恩 凱利
大衛 歐文
約翰 保羅 席克斯特
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW201841659A publication Critical patent/TW201841659A/zh
Application granted granted Critical
Publication of TWI773730B publication Critical patent/TWI773730B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW107105033A 2017-02-22 2018-02-12 治療性樹枝狀聚合物 TWI773730B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US62/461,983 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US62/488,151 2017-04-21
US201762591823P 2017-11-29 2017-11-29
US62/591,823 2017-11-29

Publications (2)

Publication Number Publication Date
TW201841659A TW201841659A (zh) 2018-12-01
TWI773730B true TWI773730B (zh) 2022-08-11

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107105033A TWI773730B (zh) 2017-02-22 2018-02-12 治療性樹枝狀聚合物

Country Status (23)

Country Link
US (4) US10314920B2 (https=)
EP (1) EP3585441A1 (https=)
JP (1) JP7074761B2 (https=)
KR (2) KR102544033B1 (https=)
CN (2) CN117582521A (https=)
AU (1) AU2018223149B2 (https=)
BR (1) BR112019016409A2 (https=)
CA (1) CA3053069A1 (https=)
CL (1) CL2019002240A1 (https=)
CO (1) CO2019009722A2 (https=)
CR (1) CR20190361A (https=)
DO (1) DOP2019000204A (https=)
EC (1) ECSP19056271A (https=)
IL (1) IL268648B (https=)
JO (1) JOP20190191B1 (https=)
MX (1) MX2019009442A (https=)
NI (1) NI201900088A (https=)
PE (1) PE20191660A1 (https=)
PH (1) PH12019501896A1 (https=)
SG (1) SG11201907334QA (https=)
TW (1) TWI773730B (https=)
UA (1) UA125655C2 (https=)
WO (1) WO2018154004A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
WO2020225307A1 (en) 2019-05-07 2020-11-12 Syddansk Universitet Mechanism for dispensing biological material
EP4034169B1 (en) * 2019-09-26 2026-02-11 Starpharma Pty Limited Therapeutic dendrimer
US20210170040A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
BR112023000320A2 (pt) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
BR112023002855A2 (pt) 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
EP4203968A4 (en) * 2020-08-31 2025-07-30 Starpharma Pty Ltd DENDRIMER-DRUG CONJUGATE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201125586A (en) * 2009-10-12 2011-08-01 Univ California Targeted nanoclusters and methods of their use
US20120035134A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab Chemical compounds
TWI392869B (zh) * 2008-07-25 2013-04-11 Nat Health Research Institutes 功能化量子點及其製備方法
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
ES2625109T3 (es) * 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
JP5989294B2 (ja) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
EP2094672B1 (en) 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
DK2376480T3 (en) 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
IN2014DN00101A (https=) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
US10730999B2 (en) * 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI392869B (zh) * 2008-07-25 2013-04-11 Nat Health Research Institutes 功能化量子點及其製備方法
TW201125586A (en) * 2009-10-12 2011-08-01 Univ California Targeted nanoclusters and methods of their use
US20120035134A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab Chemical compounds
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates

Also Published As

Publication number Publication date
JOP20190191B1 (ar) 2024-04-16
BR112019016409A2 (pt) 2020-04-07
KR20230093346A (ko) 2023-06-27
PE20191660A1 (es) 2019-11-11
CA3053069A1 (en) 2018-08-30
JOP20190191A1 (ar) 2019-08-08
WO2018154004A9 (en) 2018-12-27
US20210060172A1 (en) 2021-03-04
CL2019002240A1 (es) 2019-11-29
CN117582521A (zh) 2024-02-23
TW201841659A (zh) 2018-12-01
US10314920B2 (en) 2019-06-11
ECSP19056271A (es) 2019-08-30
AU2018223149A1 (en) 2019-10-03
AU2018223149B2 (en) 2021-04-01
KR20190112330A (ko) 2019-10-04
US10888624B2 (en) 2021-01-12
IL268648A (en) 2019-10-31
CO2019009722A2 (es) 2019-09-18
JP7074761B2 (ja) 2022-05-24
KR102544033B1 (ko) 2023-06-14
PH12019501896A1 (en) 2019-10-21
US20200069810A1 (en) 2020-03-05
IL268648B (en) 2022-04-01
SG11201907334QA (en) 2019-09-27
NI201900088A (es) 2020-03-18
EP3585441A1 (en) 2020-01-01
JP2020508985A (ja) 2020-03-26
US20240115716A1 (en) 2024-04-11
DOP2019000204A (es) 2019-08-30
CN110312531A (zh) 2019-10-08
US20180264127A1 (en) 2018-09-20
MX2019009442A (es) 2019-10-09
UA125655C2 (uk) 2022-05-11
US11717574B2 (en) 2023-08-08
WO2018154004A1 (en) 2018-08-30
CR20190361A (es) 2019-09-24

Similar Documents

Publication Publication Date Title
TWI773730B (zh) 治療性樹枝狀聚合物
TWI742074B (zh) Mcl-1抑制劑及其使用方法
TW201019963A (en) Polyethylene glycol lipid conjugates and uses thereof
CN108779117A (zh) 一类激酶抑制剂
WO2018202910A1 (en) Combination of antibiotic and bcl-2 inhibitor and uses thereof
HK40108454A (zh) 治疗性树枝状体
TWI856967B (zh) 樹枝狀體配製物
EA041072B1 (ru) Терапевтические дендримеры
HK40013356A (en) Therapeutic dendrimers
CN103772374B (zh) 一种杂环类化合物及其应用
JP5727598B2 (ja) キナーゼ阻害剤の結晶形
CA3020378C (en) Macrocyclic mcl1 inhibitors for treating cancer
WO2025088570A1 (en) Ionizable lipids and ionizable lipid nanoparticles